Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.

@article{Konstantinidou2009DualP3,
  title={Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.},
  author={Georgia Konstantinidou and Erik A. Bey and Andrea Rabellino and Katja Schuster and Michael S Maira and Adi F. Gazdar and Augusto Amici and David A. Boothman and Pier Paolo Scaglioni},
  journal={Cancer research},
  year={2009},
  volume={69 19},
  pages={7644-52}
}
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. NSCLC often harbors oncogenic K-RAS mutations that lead to the aberrant activation of several intracellular networks including the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. Oncogenic K-RAS predicts poor prognosis and resistance to treatment with ionizing radiation (IR). Oncogenic K-Ras expression in the respiratory epithelium is sufficient to initiate NSCLC… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 74 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

mTOR and cancer: insights into a complex relationship

Nature Reviews Cancer • 2006
View 12 Excerpts
Highly Influenced

Palliative thoracic radiotherapy for lung cancer: a systematic review.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 1 Excerpt

Similar Papers

Loading similar papers…